Published in Pharma Investments, Ventures and Law Weekly, December 31st, 2006
The U.S. patent (U.S. patent no. 7,138,517) is owned by Isis and is licensed exclusively to Alnylam for double-stranded RNAi therapeutic applications pursuant to the terms of their 2004 collaboration and license agreement.
"Our intellectual property estate continues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly